RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.